PP
ECYT

Paloma Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Paloma Partners’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-138,900
Closed -$208K – 2643
2017
Q2 		$208K Buy
+138,900
New +$298K ﹤0.01% 1974
2017
Q1 		– Sell
-18,017
Closed -$46K – 2379
2016
Q4 		$46K Buy
+18,017
New +$51.7K ﹤0.01% 1932

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Paloma Partners's ECYT Position: Q3 2017 in Review

Paloma Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2017, closing a stake of 138,900 shares — an estimated $208K sold.

Paloma Partners first reported a position in ECYT in Q4 2016 and held it in 2 quarters. The position peaked at $208K in Q2 2017. 63 funds tracked by Wall St. Rank hold ECYT as of Q3 2017.

  • Paloma Partners reported no remaining Endocyte, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 138,900 Endocyte, Inc. Common Stock shares in Q3 2017, an estimated $208K.
  • Paloma Partners first reported a position in Endocyte, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Paloma Partners's Endocyte, Inc. Common Stock position peaked at $208K in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.